Immunogenicity and safety of a bivalent, adjuvant system 04–adjuvanted human papillomavirus vaccine in healthy female volunteers aged 15–25: a randomized, double-blind, phase III, noninferiority clinical trial
Conclusion
The result analysis of this study supports the noninferiority of Papilloguard (Noyan Pajouhan Biopharma) to Cervarix (GlaxoSmithKline) in terms of safety and immunogenicity based on the GMT ratio. However, long-term comparative studies to evaluate the sustainability of GMT response and risk of cervical intraepithelial neoplasia grades 2–3 are needed.
Source: European Journal of Cancer Prevention - Category: Cancer & Oncology Tags: Gynecological cancer Source Type: research
More News: Belgium Health | Cancer | Cancer & Oncology | Cancer Vaccines | Cervical Cancer | Cervical Cancer Vaccine | Clinical Trials | Gardasil | Genital Warts | HPV Testing | Human Papillomavirus (HPV) | Iran Health | Middle East Health | Study | Vaccines | Women